New series of antiprion compounds: Pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation

Journal of Medicinal Chemistry

Volumn 50, Issue 21, 2007, Pages 5053-5056

  Kimata, Ayako ^a   Nakagawa, Hidehiko ^a   Ohyama, Ryo ^a   Fukuuchi, Tomoko ^a   Ohta, Shigeru ^a   Suzuki, Takayoshi ^a   Miyata, Naoki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOHEXYL DERIVATIVE; 3 (4 NITROPHENYL) DERIVATIVE; 3 ISOPROPENYL DERIVATIVE; 4 BENZOYL DERIVATIVE; ANTIPRION COMPOUND; HYDROXYL RADICAL; NORPHENAZONE; PRION PROTEIN; PROTEIN INHIBITOR; PROTEINASE; PYRAZOLONE DERIVATIVE; SCAVENGER; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICAL SCAVENGERS; HYDROXYL RADICAL; MICE; PRPSC PROTEINS; PYRAZOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDE DISMUTASE;

EID: 35348888465     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070688r     Document Type: Article

References (26)

1. Prusiner, S. B. Molecular biology of prion diseases. Science 1991, 252, 1515-1522.
2. Brown, D. R.; Qin, K.; Herms, J. W.; Madlung, A.; Manson, J.; Strome, R.; Fraser, P. E.; Kruck, T.; von Bohlen, A.; Schulz-Schaeffer, W.; Giese, A.; Westaway, D.; Kretzschmar, H. The cellular prion protein binds copper in vivo. Nature 1997, 390, 684-687.
3. Jackson, G. S.; Murray, I.; Hosszu, L. L.; Gibbs, N.; Waltho, J. P.; Clarke, A. R.; Collinge, J. Location and properties of metal-binding sites on the human prion protein. Proc. Natl. Acad. Sci U.S.A. 2001, 98, 8531-8535.
4. Brown, D. R.; Wong, B. S.; Hafiz, F.; Clive, C.; Haswell, S. J.; Jones, I. M. Normal prion protein has an activity like that of superoxide dismutase. Biochem. J. 1999, 344, 1-5.
5. Pauly, P. C.; Harris, D. A. J. Copper stimulates endocytosis of the prion protein. J. Biol. Chem. 1998, 273, 33107-33110.
6. Miura, T.; Sasaki, S.; Toyama, A.; Takeuchi, H. Copper reduction by the octapeptide repeat region of prion protein: pH dependence and implications in cellular copper uptake. Biochemistry 2005, 44, 8712-8720.
7. C may inhibit prion disease propagation. Brain Res. 2003, 993, 192-200.
8. McKenzie, D.; Bartz, J.; Mirwald, J.; Olander, D.; Marsh, R.; Aiken, J. Reversibility of scrapie inactivation is enhanced by copper. J. Biol. Chem. 1998, 273, 25545-25547.
9. Sigurdsson, E. M.; Brown, D. R.; Alim, M. A.; Scholtzova, H.; Carp, R.; Meeker, H. C.; Prelli, F.; Frangione, B.; Wisniewski, T. Copper chelation delays the onset of prion disease. J. Biol. Chem. 2003, 278, 46199-46202.
10. Kocisko, D. A.; Baron, G. S.; Rubenstein, R.; Chen, J.; Kuizon, S.; Caughey, B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol. 2003, 77 10288-10294.
11. Murakami-Kubo, I.; Doh-ura, K.; Ishikawa, K.; Kawatake, S.; Sasaki, K.; Kira, J.; Ohta, S.; Iwaki, T. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J. Virol. 2004, 78, 1281-1288.
12. Kilingenstein, R.; Melnyk, P.; Leliveld, R.; Ryckebusch, A.; Korth, C. Similar structure-activity relationships of quinoline derivatives for antiprion and antimalarial effects. J. Med. Chem. 2006, 49, 5300-5308.
13. Ingrosso, L.; Ladogana, A.; Pocchiari, M. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 1995, 69, 506-508.
14. Sellarajha, S.; Lekishvili, T.; Bowring, C.; Thompsett, A. R.; Rudyk, H.; Birkett, C. R.; Brown, D. R.; Gilbert, I. H. Synthesis of analogues of Congo red and evaluation of their anti-prion activity. J. Med. Chem. 2004, 47, 5515-5534.
15. May, B. C. H.; Zorn, J. A.; Witkop, J.; Sherrill, J.; Wallace, A. C.; Legname, G.; Prusiner, S. B.; Cohen, F. E. Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics. J. Med. Chem. 2007, 50, 65-73.
16. Watanabe, T.; Yuki, S.; Egawa, M.; Nishi, H. Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 1994, 268, 1597-1604.
17. Kawai, H.; Nakai, H.; Suga, M.; Yuki, S.; Watanabe, T.; Saito, K. I. Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 1997, 281, 921-927.
18. Wu, T. W.; Zeng, L. H.; Wu, J.; Fung, K. P. Myocardial protection of MCI-186 in rabbit ischemia-reperfusion. Life Sci. 2002, 71, 2249-2255.
19. Doh-ura, K.; Iwaki, T.; Caughey, B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 2000, 74, 4894-4897.
20. Ishikawa, K.; Doh-ura, K.; Kudo, Y.; Nishida, N.; Murakami-Kubo, I.; Ando, Y.; Sawada, T.; Iwaki, T. Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 2004, 85, 1785-1790.
21. Milhavet, O.; McMahon, H. E.; Rachidi, W.; Nishida, N.; Katamine, S.; Mange, A.; Arlotto, M.; Casanova, D.; Riondel, J.; Favier, A.; Lehmann, S. Prion infection impairs the cellular response to oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13937-13942.
22. Nakagawa, H.; Ohyama, R.; Kimata, A.; Suzuki, T.; Miyata, N. Hydroxyl radical scavenging by edaravone derivatives: Efficient scavenging by 3-methyl-1-(pyridine-2-yl)-5-pyrazolone with an intramolecular base. Bioorg. Med. Chem. Lett. 2006, 16, 5939-5942.
23. Ono, S.; Okazaki, K.; Sakurai, M.; Inoue, Y.; Density functional study of the radical reactions of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186): implication for the biological function of MCI-186 as a highly potent antioxidative radical scavenger. J. Phys. Chem. A 1997, 101, 3769-3775.
24. Fukuuchi, T.; Doh-ura, K.; Yoshihara, S.; Ohta, S. Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug. Bioorg. Med. Chem. Lett. 2006, 16, 5982-5987.
25. Vosburgh, W. C.; Cooper, G. R. Complex ions. I. The identification of complex ions in solution by spectrophotometric measurements. J. Am. Chem. Soc. 1941, 63, 437-442.
26. Doh-ura, K.; Tamura, K.; Karube, Y.; Naito, M.; Tsuruo, T.; Kataoka, Y. Chelating compound, chrysoidine, is more effective in both antiprion activity and brain endothelial permeability than quinacrine. Cell. Mol. Neurobiol. 2007, 27, 303-316.